Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Canada
Deutschland
España
France
Italia
Schweiz (DE)
Suisse (FR)
United Kingdom
United States
Settings
Dynamic quotes
OFF
ON
Markets
Equities
North America
Europe
Asia
Oceania
Middle East
»
More Equities
Indexes
DOW JONES
S&P 500
NASDAQ 100
TSX COMP
NIKKEI 225
»
More Indexes
Currency / Forex
EUR / USD
GBP / USD
USD / JPY
USD / CAD
AUD / USD
»
More Currencies
Commodities
GOLD
Crude Oil (WTI)
Crude Oil (BRENT)
SILVER
PLATINUM
»
More Commodities
Trackers & ETF
Rankings and News
Advanced Search
Cryptocurrencies
BITCOIN
ETHEREUM
News
Latest News
Companies
Markets
Economy
Currency / Forex
Commodities
Interest Rates
Business Leaders
Cryptocurrencies
Cybersecurity
Economic calendar
Listed company
Analyst reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit warnings
Appointments
Press Releases
Events
Corporate actions
Financial calendar
Sector News
Energy
Basic Materials
Industrials
Consumer Cyclical
Consumer Non-Cyclical
Financials
Healthcare
Technology
Telecommunications Services
Utilities
Analysis
All Analysis
Must Read
Daily briefing
Weekly market update
Stock Trading Strategies
Stock Picks
All stock picks
Subscribe
Portfolios
My Portfolio
Virtual portfolios
MarketScreener Portfolios
USA Portfolio
European Portfolio
Asian Portfolio
Watchlists
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment style
Yield stocks
Growth stocks
Undervalued Stocks
Investment themes
Place your bets
Europe's family businesses
Let’s all cycle!
Fintechs
Ageing Population
Robotics
Cybersecurity
Financial Data
Gold and Silver
Top / Flop
Top News
Most Read News
Hot News
Top Fundamentals
Top Capitalization
Top Yield
Top PER
Top Consensus
Top Fundamentals
Top Technicals
Top RSI
Unusual volumes
Top Gaps
Top STIM
Breakouts
Trends
Top Movers
Top USA
Top Canada
Top U.K.
Top Germany
Top Europe
Top Asia
Screeners
Investment selections
Place your bets
Europe's family businesses
Let’s all cycle!
Fintechs
Ageing Population
Robotics
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Growth stocks
Yield stocks
Low valuations
Stock Screener Home
My Screeners
All my stocks
Watchlists
Virtual Portfolios
Tools
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Dynamic chart
Financial calendar
Economic calendar
Sector research
Currency converter
ProRealTime Trading
Our Services
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Our Stock Picks
Thematic Investment Lists
Stock Screener
MarketScreener Homepage
>
Equities
>
NASDAQ OMX COPENHAGEN
>
Genmab A/S
GMAB
DK0010272202
GENMAB A/S
(GMAB)
Add to my list
Report
Delayed NASDAQ OMX COPENHAGEN -
01/15 10:59:56 am
2687
DKK
+0.94%
01/15
GENMAB A/S
: to Receive $30 Million Milestone Payment from Janssen Over FDA Approval of Darzalex Faspro for Amyloidosis
MT
01/15
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
GL
01/15
GENMAB A/S
: HC Wainwright Adjusts Genmab A/S' Price Target to $49 from $44, Keeps Buy Rating
MT
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Summary
Most relevant
All News
Press Releases
Official Publications
Sector news
MarketScreener Strategies
Analyst Recommendations
Analyst Recommendations on GENMAB A/S
01/15
GENMAB A/S
: HC Wainwright Adjusts Genmab A/S' Price Target to $49 from $44, Kee..
MT
01/04
GENMAB A/S
: RBC Capital Adjusts Genmab A/S' Price Target to $46 From $40, Maint..
MT
2020
SVB Leerink Adjusts Genmab's Price Target to $34 from $36, Keeps Market Perfo..
MT
2020
HC Wainwright Adjusts Genmab's Price Target to $44 From $45, Keeps at Buy
MT
2020
Morgan Stanley Adjusts Genmab's Price Target to $37 From $35, Keeps at Overwe..
MT
2020
RBC Capital Adjusts Genmab A/S' Price Target to $40 From $38, Maintains Outpe..
MT
2020
HC Wainwright Adjusts Genmab's Price Target to $45 From $42, Reiterates Buy R..
MT
2020
GLAXOSMITHKLINE
: GSK's blood cancer drug wins European panel thumbs-up
RE
2020
GENMAB A/S
: GSK's blood cancer drug wins European panel thumbs-up
RE
2020
GLAXOSMITHKLINE
: FDA panel votes in favor of approving GSK's multiple myeloma d..
RE
2020
GENMAB
: Darzalex Meets Main Endpoint in Light-Chain Amyloidosis Study
DJ
Stock Trading Strategies
TRADING
The underlying trend is to the upside
More Stock Trading Analysis
Official Publications
2020
3rd quarter results
2020
2nd quarter results
2020
Half-year report
2020
1st quarter results
2020
Proxy Statments
2019
Annual Report
More Official Publications
Upcoming event on GENMAB A/S
02/24/21
Jahr 2020 Ergebnisveröffentlichung (geplant)
Company calendar
Upcoming sector events
01/21/21
BIOCON LIMITED
: Q3 2021 Earnings Release
01/27/21
LONZA GROUP LTD
: FY 2020 Earnings Release
02/03/21
VERTEX PHARMACEUTICALS INCORPORATED
: FY 2020 Earnings Release (Projected)
02/03/21
QIAGEN N.V.
: FY 2020 Earnings Release (Projected)
More events
Sector
Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs
Slave